KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Research & Development (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Research & Development for 13 consecutive years, with $57.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 6.76% year-over-year to $57.9 million, compared with a TTM value of $206.0 million through Dec 2025, down 5.28%, and an annual FY2025 reading of $206.0 million, down 5.28% over the prior year.
  • Research & Development was $57.9 million for Q4 2025 at Travere Therapeutics, up from $51.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $66.5 million in Q2 2023 and bottomed at $46.9 million in Q1 2025.
  • Average Research & Development over 5 years is $55.2 million, with a median of $55.5 million recorded in 2022.
  • The sharpest move saw Research & Development skyrocketed 68.26% in 2021, then fell 18.29% in 2024.
  • Year by year, Research & Development stood at $53.0 million in 2021, then increased by 9.6% to $58.1 million in 2022, then increased by 2.86% to $59.7 million in 2023, then rose by 3.88% to $62.1 million in 2024, then fell by 6.76% to $57.9 million in 2025.
  • Business Quant data shows Research & Development for TVTX at $57.9 million in Q4 2025, $51.9 million in Q3 2025, and $49.4 million in Q2 2025.